Protalix BioTherapeutics (PLX) Convertible Debt (2013 - 2023)

Protalix BioTherapeutics has reported Convertible Debt for 11 years, with the latest figure at $20.4 million in Q4 2023.

• On a quarterly basis, Convertible Debt fell 27.56% year-over-year to $20.4 million in Q4 2023; TTM through Dec 2023 was $20.4 million, a 27.56% decrease from a year earlier, with the FY2023 full-year figure at $20.4 million, down 27.56% from the prior year.
• Convertible Debt was $20.4 million for Q4 2023 at Protalix BioTherapeutics, up from $20.1 million in the prior quarter.
• The five-year high for Convertible Debt was $53.5 million in Q3 2020, with the low at $20.1 million in Q2 2023.
• Average Convertible Debt over 5 years is $37.1 million, with a median of $28.2 million recorded in 2022.
• The sharpest annual moves came in 2020 and 2021: Convertible Debt gained 6.66% in 2020, then slumped 48.01% in 2021.
• Over 5 years, Convertible Debt stood at $51.0 million in 2019, then climbed by 5.0% to $53.5 million in 2020, then tumbled by 47.88% to $27.9 million in 2021, then rose by 1.08% to $28.2 million in 2022, then declined by 27.56% to $20.4 million in 2023.
• The last three Convertible Debt figures came in at $20.4 million (Q4 2023), $20.1 million (Q2 2023), and $28.3 million (Q1 2023), per Business Quant data.